Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486543 | 0.91 | LRRK2 (0.44) | LRRK2KIF11LARS1ALDH1A1PRKCI | |
| SCHEMBL8519013 | 0.78 | ALDH1A1 (0.57) | KIF11ALDH1A1 | |
| SCHEMBL30690007 | 0.77 | ALOX5 (0.53) | LRRK2KIF11LARS1ALOX5NR1H2 | |
| SCHEMBL17367960 | 0.77 | ALOX5 (0.53) | LRRK2KIF11LARS1ALOX5NR1H2 | |
| Hydrochloric Acid SCHEMBL31280707 | 0.76 | ALOX5 (0.52) | LRRK2KIF11LARS1ALOX5NR1H2 | |
| Hydrochloric Acid SCHEMBL26666885 | 0.76 | ALOX5 (0.52) | LRRK2KIF11LARS1ALOX5NR1H2 | |
| SCHEMBL7430043 | 0.75 | ALDH1A1 (0.57) | LRRK2KIF11LARS1ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL1138791 | 0.74 | CYP17A1 (0.53) | KIF11PRKCI | |
| SCHEMBL1138793 | 0.74 | EPHX1 (0.43) | LRRK2KIF11PRKCINOTUM | |
| SCHEMBL31627321 | 0.74 | RXFP1 (0.42) | NR1H2NR1H3PTGES2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| US-7417043-B2 | Modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-08-26 | — | — | US | disclosed |
| US-20060135531-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1240142-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2005-10-19 | — | — | EP | disclosed |
| US-6903120-B2 | A 4-(phenyl-N- alkyl)-piperidine derivatives for treatment of central nervous system disorders, Parkinson disease, anxiety, dyskinesias, dystonias, Tourette's disease, psychoses, hallucinoses, sleep disorder, autism | A. CARLSSON RESEARCH AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | disclosed |
| EP-1240142-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135531-A1 | Modulators of dopamine neurotransmission | SLC6A3, BRS3, CHRNA3 | LRRK2 193/4885KIF11 2041/4885LARS1 3621/4885 |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | LRRK2 321/4885KIF11 4377/4885LARS1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.